Press Releases

BioMS Medical Hires Multiple Sclerosis Clinical Trial Expert

Dr. Leopold Arfors appointed Medical Director of BioMS

Edmonton, Alberta, July 22, 2004 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce the appointment of Leopold Arfors, M.D., Ph.D., to the newly created position of Medical Director.

”Dr. Arfors has extensive experience in drug development and has designed and completed numerous clinical trials, in particular for multiple sclerosis products,” said Kevin Giese, President of BioMS Medical. ”With our pivotal trial for MBP8298 in secondary progressive MS about to commence, Dr. Arfors will play a key role in the excuetion of this clinical trial.”

Prior to joining BioMS Medical, Dr. Arfors was the Product Medical Director at AstraZeneca, heading the clinical development of drugs for MS and other autoimmune diseases. He was also a member of AstraZeneca's MS disease area specialist team for validation of potential biomarkers for MS clinical trials and evaluation of in-licensing opportunities.

Dr. Leopold Arfors holds an M.D. from the Karolinska Institute in Stockholm, Sweden, where he also earned his Ph.D. He is board certified in clinical immunology, as well as internal medicine with sub-specialization in rheumatology and has served in that capacity for many years at the Karolinska University Hospital in Stockholm. His experience also entails several years at the SBL immunological laboratory and consultancy rheumatology at the Kronan pain clinic in Stockholm. His pharmaceutical industry experience dates back to 1995, when he joined the Swedish company Astra; which through a merger became part of AstraZeneca.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.